Forums and Workshops (April 29)
Forums and Workshops (April 29)
Chaired private and exclusive roundtable series.
11.10am (1hr 40mins) Roundtable One
- M&A, deal environment, anti-trust landscape analysis, general discussion and peer commentary from BD heads
11.10 Introductions
11.15 Current and Impending Anti-trust and Regulatory Threats
General Discussion and Peer Perspectives
- Perceptions and perspectives on current deal making environment: what are BD heads observing and how are they responding?
- How should big pharma M&A strategies evolve given the regulatory and anti-trust context?
For further information regarding the Pharma BD Leaders Forum, please contact:
Matthew Pullan, Managing Director, LSX
16:00 - Welcome and Introductions
Moderator: Fiona McFarlane, Legal Director, Bird & Bird
16:05 - Early Considerations for Life Sciences Companies – Funding and beyond
This will be a session for executives of early-stage life sciences and healthcare companies to share their experiences of running a start-up. There will be a short introduction to venture capital financing and other foundational issues, followed by a panel discussion and Q&A session where the attendees can ask questions of company representatives who have successfully navigated the early stage funding arena and investor-side representatives who provide funding to early-stage companies. The session will be operated under the Chatham House Rule to promote a free-flowing exchange of ideas in a confidential and productive environment and to encourage open and honest discussions.
Fiona McFarlane, Legal Director, Bird & Bird
Mario Subramaniam, Partner, Bird & Bird
16:35 - Case Study
Jette Cowan, Head of Commercial, Pharmaceutical, RSSL
17:05 - CEO-Led Case Study - Successful Adaptation of Fundraising Strategy in the Life Sciences/Biotech Sector
- Initially funded to Phase 1 for lead asset, planned Series A for Phase 2 study
- Market shift led to investor demand for more de-risking data before committing to larger funding
- Adapted strategy by advancing FDA "IND" opening, a significant value inflection point
- Successfully opened pre-Series A convertible note for smaller Phase 2a study, paving the way for larger funding round with a leading VC partner
John Boghossian, CEO, Kanna Health
17:25 - General Discussion and Q&A
17.40 - End of Forum
2pm (2hrs) Roundtable Two – Global BD Heads only
Peer discussion and exploration of solutions to presented challenges.
Potential topics to include:
- IRA developments
- M&A landscape
- Current challenges and success stories
- Anti-trust
- Regulatory update
- AI and relevance, impact on deal making
For further information regarding the Pharma BD Leaders Forum, please contact:
Matthew Pullan, Managing Director, LSX